121 related articles for article (PubMed ID: 32696321)
1. High Doses of Δ
Kopjar N; Fuchs N; Brčić Karačonji I; Žunec S; Katić A; Kozina G; Lucić Vrdoljak A
Clin Drug Investig; 2020 Sep; 40(9):775-787. PubMed ID: 32696321
[TBL] [Abstract][Full Text] [Related]
2. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM; Goey AKL; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2018 Oct; 57(10):1229-1254. PubMed ID: 29520731
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of irinotecan metabolism and transport: an update.
Smith NF; Figg WD; Sparreboom A
Toxicol In Vitro; 2006 Mar; 20(2):163-75. PubMed ID: 16271446
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
[TBL] [Abstract][Full Text] [Related]
5. Effects of Δ
Prester L; Mikolić A; Jurič A; Fuchs N; Neuberg M; Lucić Vrdoljak A; Brčić Karačonji I
Chem Biol Interact; 2018 Oct; 294():128-134. PubMed ID: 30130528
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers.
Lucić Vrdoljak A; Fuchs N; Mikolić A; Žunec S; Brčić Karačonji I; Jurič A; Prester L; Micek V; Neuberg M; Čanović S; Mršić G; Kopjar N
Molecules; 2018 Jun; 23(6):. PubMed ID: 29865166
[TBL] [Abstract][Full Text] [Related]
7. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S
Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513
[TBL] [Abstract][Full Text] [Related]
10. Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
Wolowich WR; Greif R; Kleine-Brueggeney M; Bernhard W; Theiler L
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):691-711. PubMed ID: 31114948
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
12. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
13. CYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo-delta(8)-tetrahydrocannabinol in human liver microsomes.
Matsunaga T; Kishi N; Higuchi S; Watanabe K; Ohshima T; Yamamoto I
Drug Metab Dispos; 2000 Nov; 28(11):1291-6. PubMed ID: 11038155
[TBL] [Abstract][Full Text] [Related]
14. Optimisation of a gas chromatography-mass spectrometry method for the simultaneous determination of tetrahydrocannabinol and its metabolites in rat urine.
Fuchs N; Miljanić A; Katić A; Brajenović N; Micek V; Fuchs R; Karačonji IB
Arh Hig Rada Toksikol; 2019 Dec; 70(4):325-331. PubMed ID: 32623866
[TBL] [Abstract][Full Text] [Related]
15. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.
Watanabe K; Yamaori S; Funahashi T; Kimura T; Yamamoto I
Life Sci; 2007 Mar; 80(15):1415-9. PubMed ID: 17303175
[TBL] [Abstract][Full Text] [Related]
18. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
van der Bol JM; Loos WJ; de Jong FA; van Meerten E; Konings IR; Lam MH; de Bruijn P; Wiemer EA; Verweij J; Mathijssen RH
Eur J Cancer; 2011 Apr; 47(6):831-8. PubMed ID: 21216137
[TBL] [Abstract][Full Text] [Related]
19. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
[TBL] [Abstract][Full Text] [Related]
20. Quantifying Hepatic Enzyme Kinetics of (-)-∆
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2019 Jul; 47(7):743-752. PubMed ID: 31048453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
